Analysis of Anticoagulant Utilization in the Czech Republic in the period from 2007 to 2016

Analysis of anticoagulant utilization in the Czech republic in the period from 2007 to 2016 Author: Zuzana Hochelová1 Supervisor: PharmDr. Eva Zimčíková, Ph.D.1 Consultant: PharmDr. Kateřina Malá, Ph.D.1 1 Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic Introduction: Anticoagulants are drugs that reduce blood clotting and prevent the formation of blood clots. In the Czech Republic - antagonists of vitamin K-warfarin, direct oral inhibitors of factor Xa-rivaroxaban, apixaban, edoxaban, direct oral inhibitors trombin - dabigatran, parenteral anticoagulants - heparin, low-molecular heparin, fondaparinux, oral and parenteral hirudin are used. Objective: The objective of this diploma thesis was to assess the consumption of oral and parenteral anticoagulants in the Czech Republic from 01. 01. 2007 to 31. 12. 2016, based on the data from the State Institute of Drug Control (SIDC). Methods: ATC/DDD methodology was applied. The research consisted of a retrospective analysis of the SIDC database. All oral and parental anticoagulants approved in the CR were included in the study. Drug utilization was calculated as number of defined daily doses per thousands of inhabitants per day (DID). The data on the number of residents was acquired from..